| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 5.89 | 0.20 (+3.51%) | 3.00 - 6.56 | 912.4 thousand (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 5.73 |
|---|---|
| Previous Close | 5.69 |
| Day's Range | 5.73 - 5.91 |
| Market Cap | 687.8M |
| Avg Volume (10 Day) | 1.3M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.51 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
PR Newswire - Wednesday 05/15/2013 8:00 AM ET
Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
PR Newswire - Wednesday 05/08/2013 8:00 AM ET
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
PR Newswire - Monday 05/06/2013 4:05 PM ET
Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
PR Newswire - Monday 05/06/2013 4:00 PM ET
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2013 On May 6, 2013
PR Newswire - Monday 04/29/2013 1:28 PM ET
| ARRY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -22.38% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 10.61 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 6.75 | -8.66% |
| Exact Sciences Corp | 10.56 | -2.40% |
| China Biologic Products Inc | 26.48 | +1.30% |
| Optimer Pharmaceuticals Inc | 14.97 | -0.93% |
| Dendreon Corp | 4.01 | +1.01% |
Data is delayed by at least 15 min.